Chiome Bioscience

Chiome Bioscience EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Chiome Bioscience (4583.T) as of Oct 17, 2026 is -56.72 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -41.75 % — a change of 35.83% (lower).

EBIT/Assets

-56.72 %

YoY

35.83%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Chiome Bioscience is 2025 -56.72 % . Operating Income to Assets Ratio (EBIT/Assets) of Chiome Bioscience was 2024 -41.75 % . It decreases by 35.83% lower compared to the previous year.

The Chiome Bioscience EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
-54.36 JPY
Jan 1, 2019
-49.93 JPY
Jan 1, 2020
-36.73 JPY
Jan 1, 2021
-62.33 JPY
Jan 1, 2022
-56.81 JPY
Jan 1, 2023
-68.81 JPY
Jan 1, 2024
-41.75 JPY
Jan 1, 2025
-56.72 JPY
The Chiome Bioscience EBIT/Assets history
YEAREBIT/AssetsYoY
-56.72 %+35.83%
-41.75 %-39.32%
-68.81 %+21.12%
-56.81 %-8.85%
-62.33 %+69.69%
-36.73 %-26.43%
-49.93 %-8.16%
-54.36 %+170.60%
-20.09 %-7.70%
-21.76 %-15.70%
-25.82 %+39.98%
-18.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Chiome Bioscience Stock analysis

What does Chiome Bioscience do? Chiome Bioscience Inc is a Health Care company based in Shibuya-Ku, Japan. The company has 49 employees and went public on December 20, 2011. It operates in the Life Sciences Tools & Services industry. Chiome Bioscience develops and sells antibody drugs using the Autonomous Diversifying Library (ADLib) system. Its business segments include Drug Discovery, focusing on R&D of specific antibodies for pharmaceutical companies, and Drug Discovery Support, which develops lead antibodies for therapeutic drugs through collaborations with pharmaceutical firms in Japan and overseas. Chiome Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Chiome Bioscience stock

Operating Income to Assets Ratio (EBIT/Assets) of Chiome Bioscience is -56.72 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Chiome Bioscience changed from -41.75 % to -56.72 %, representing a 35.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Chiome Bioscience since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Chiome Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Chiome Bioscience

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Chiome Bioscience